Summary: ALK invests in development of a peanut allergy vaccine

ALK has signed an agreement to invest EUR 2 million in the French biotech
company DBV Technologies as part of a follow-up equity financing of the
company.

The investment in DBV Technologies provides an opportunity for ALK to enter a
collaboration on developing a new promising vaccine against peanut allergy. The
peanut allergy vaccine, which is currently being developed by DBV Technologies,
is based on a proprietary electro charged patch technology offering gradual
uptake of the active vaccine ingredients through the skin.

Peanut allergy is one of the most severe food allergies. Peanut allergic
patients may experience severe allergic reactions or even anaphylaxis when
accidentally exposed to peanut allergens.

Currently, there are no allergy vaccine products or proven technologies
available for the treatment of patients suffering from peanut allergy. As a
result, patients rely on strict avoidance of peanuts combined with adrenaline
auto-injectors for self-administration in case of an allergic emergency.

As part of the agreement, President and CEO Jens Bager will join DBV
Technologies' Board of Directors. In accordance with its accounting policies,
ALK will record the investment on the balance sheet under long-term financial
assets.


ALK-Abelló A/S

Jens Bager
President & CEO


Contact person:
Jens Bager, President and CEO, tel. +45 4574 7576

fm-01-2009-uk.pdf